4P-Pharma & Delta 4 Join Forces to Find & Develop Treatments for a Rare Autoimmune Chronic Liver Disease

4P-Pharma and Delta 4 recently announced the signing of a collaboration agreement in which both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available.

Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signaling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta 4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta 4’s and 4P-Pharma’s teams aim to bring an innovative drug candidate to patients affected by this rare disease.

“4P-Pharma aims to bring breakthrough curative solutions with a strong scientific rationale to patients,” said Revital Rattenbach, CEO of 4P-Pharma. “With this partnership, we will benefit from Delta 4’s AI proprietary computational analytics platform to identify breakthrough drug candidates. Combined with our drug development expertise, together we will accelerate the identification of drug candidates for patients affected by this rare liver disease. It underlines our shared commitment to bring breakthrough solutions to patients.”

“We are looking forward to joining forces with 4P-Pharma to make a difference for patients who are suffering from a devastating disease,” added Kurt Herpel, CEO, Delta 4. “4P-Pharma has consistently proven the viability of their rigorous and focused approach to advancing promising drug candidates up the development pipeline. Specifically, we are excited about the opportunity to apply our platform to a new disease area and to work with 4P-Pharma to make a difference in the treatment of these liver impaired patients.”

4P-Pharma is a French clinical-stage company founded in 2014, dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. It aims to develop innovative programs with strong scientific rationale, sourced from the top academic research labs and AI based biotechs. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities located within Pasteur Institute of Lille (France), combined with single product vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.

Delta 4 is a digital drug discovery and development company, focusing on the discovery of novel indications for approved drugs. Delta 4 combines in-silico drug discovery and big data analysis with extensive expertise in molecular biology and bioinformatics to a powerful proprietary drug discovery platform. Delta 4 uses this platform for the discovery of promising drug leads. The drug leads thus generated are backed by a strong mechanistic hypothesis that significantly reduces the time to a clinical proof-of-concept of validated compounds.